{"id":5189,"date":"2016-12-03T05:00:51","date_gmt":"2016-12-03T10:00:51","guid":{"rendered":"https:\/\/medicarereport.org\/?p=5189"},"modified":"2016-12-02T11:02:42","modified_gmt":"2016-12-02T16:02:42","slug":"mylan-ceo-accepts-full-responsibility-for-epipen-price-hikes-but-offers-little-explanation","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=5189","title":{"rendered":"Mylan CEO accepts full responsibility for EpiPen price hikes, but offers little explanation"},"content":{"rendered":"<p>(By Ed Silverman for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap\">I<\/span>n a rare appearance since the EpiPen controversy flared\u00a0this summer, Mylan Pharmaceuticals CEO Heather Bresch\u00a0accepted \u201cfull responsibility\u201d Thursday for the price hikes that caused national outrage. <a href=\"https:\/\/www.statnews.com\/pharmalot\/2016\/12\/01\/mylan-ceo-responsibility-epipen-price\/?_hsenc=p2ANqtz--cXymktS-wtd7gR7WOg1uBUcahlI9baV1LPbDs19AitTtun3AhBO8fVIc57MgDPfadzjX4wPC3CEbd4SDrJbE-mUbMCw&amp;_hsmi=38601283\" target=\"_blank\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"stat-logo\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Ed Silverman for STAT) In a rare appearance since the EpiPen controversy flared\u00a0this summer, Mylan Pharmaceuticals CEO Heather Bresch\u00a0accepted<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-5189","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5189"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5189\/revisions"}],"predecessor-version":[{"id":5190,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/5189\/revisions\/5190"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}